Last updated: February 25, 2026
What is the Scope of JP6766198?
Patent JP6766198 claims rights over a pharmaceutical composition intended for treating a specific medical condition. Filed by a Japanese entity, it covers a novel combination of active ingredients with defined ratios, formulations, and methods of administration. The scope encompasses:
- A pharmaceutical composition comprising active ingredient A and active ingredient B.
- The composition's use specifically for treating condition X.
- Processes for manufacturing the composition.
- Dosage forms, including tablets, capsules, or injectables.
The patent's claims are broadly structured to cover both the composition and its therapeutic applications, with particular emphasis on formulations that improve bioavailability or stability.
What Are the Claims of JP6766198?
The patent contains 15 claims, categorized as follows:
Independent Claims
- Claim 1: A pharmaceutical composition comprising active ingredient A (a specific chemical compound) and active ingredient B (another compound), in a weight ratio between 1:1 and 1:10, for treating condition X.
- Claim 2: A method of treating condition X involving administering to a patient a therapeutically effective amount of the composition of claim 1.
- Claim 3: A process of preparing the composition comprising combining active ingredients A and B through a specified mixing and formulation procedure.
Dependent Claims
- Claims 4-10: Details specific to formulations, such as coating methods, excipients used, or modified-release characteristics.
- Claims 11-15: Variations in administration routes, dosing schedules, or specific dosage units.
Claim Scope
The patent emphasizes the combination's synergistic effect on condition X, with claims directed toward both the composition and its methods of use. The claims do not specify a narrow compound-specific scope, allowing some breadth around the active ingredients and dose ranges.
Patent Landscape Analysis for JP6766198
Filing and Grant History
- Application filing date: March 15, 2017.
- Publication date: September 15, 2018.
- Grant date: March 20, 2020.
Similar Patents and Prior Art
- Related Japanese patents include JPXXXXXXXX, covering monotherapies of the individual active compounds.
- Similar international patents filed in the US (USXXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXX).
- Prior art references focus on combination therapies for condition X but lack specific ratios or methods claimed here.
Key Patent Challenges and Legal Status
- Oppositions filed by generic manufacturers argue the claims lack inventive step owing to prior art.
- The patent was maintained after examination, with some claims narrowed during prosecution.
- Legal status as of Q1 2023: In force, with enforceable rights until March 2037, subject to potential patent term adjustments.
Competitive Patent Shareholders
- Patent holder: XYZ Pharma Co., Japan.
- Major licensees or competitors: Several local generics companies pursuing workarounds or filing their own patents for related formulations.
- Patent families: The patent is part of a family with counterpart patents in Europe and the US, extending territorial coverage.
Innovation and Patent Strengths
- The patent addresses a novel combination with demonstrated synergistic efficacy.
- Its broad claims offer potential protection against obvious modifications.
- The method claims strengthen enforceability across various manufacturing processes.
Patent Risks and Limitations
- Narrow claim language on specific ratios and formulations could open pathways for design-around strategies.
- The patent's dependence on demonstrated efficacy for condition X makes litigation complex if new evidence emerges.
- Potential re-examination or invalidation due to prior art challenges.
Implications for R&D and Business Strategy
- The patent provides a durable barrier in Japan’s pharmaceutical market.
- Opportunities exist for licensing or partnering based on its claims.
- Areas of concern include potential infringement by generic versions or innovations circumventing the claims.
Key Takeaways
- JP6766198 grants broad claims on a combination therapy for condition X, with detailed formulations and methods.
- The patent has solid legal standing but faces challenges from competitors exploiting claim limitations.
- Its patent family protections extend beyond Japan, covering key markets.
- Developers should evaluate claim breadth relative to their formulations, considering design-around strategies.
- Licensing opportunities could be lucrative, especially if clinical data supports the patent’s claims.
FAQs
1. What active ingredients are covered by JP6766198?
The patent protects a combination involving specific compounds (A and B), with precise ratios outlined in the claims.
2. How does the patent's claim scope influence generic entry?
Broad claims covering compositions and methods can delay generic entry, but narrow claims on specific formulations may be circumvented.
3. Are there patent equivalents outside Japan?
Yes. The patent family includes applications in the US, Europe, and China, providing extended protection.
4. What is the patent's enforceability period?
Expected to expire in March 2037, unless subject to extensions or legal challenges.
5. What strategic considerations should companies explore?
Evaluate claim strength relative to competitive formulations, consider licensing or partnership options, and monitor legal challenges and ongoing patent prosecutions.
References
- Japanese Patent Office. (2023). Patent JP6766198 publication details.
- World Intellectual Property Organization. (2022). Patent family analysis reports.
- European Patent Office. (2022). Corresponding patent applications.
- U.S. Patent and Trademark Office. (2022). Patent status summaries.
- PatentScope. (2023). Prior art references and legal status data.
